Treatment of immediate hypersensitivity diseases with aryl hydantoins
US4241073A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | May 14, 1979 |
| Grant date | Dec 23, 1980 |
| Priority date | — |
| Expiry date | May 14, 1999 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D233/78
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Novel hydantoin compounds are described of the formula (I): ##STR1## wherein Ar is phenyl optionally substituted by up to three radicals selected from the group comprising C.sub.1-6 alkoxy, halogen, 1,3-dioxol-2-yl, hydroxy C.sub.1-4 alkoxy C.sub.1-4 alkyl, phenyl, hydroxyl, nitrile, C.sub.1-4 haloalkyl, C.sub.1-4 alkyl, C.sub.2-4 alkenyloxy, C.sub.1-4 alkoxycarbonyl or phenoxy optionally substituted by C.sub.1-4 haloalkyl, C.sub.1-4 alkoxy or halogen; PA1 or is thiophene optionally substituted by phenyl or by one or two C.sub.1-4 alkyl groups; PA1 R.sup.1 and R.sup.2 are independently hydrogen or taken together represent a chemical bond; PA1 R.sup.3 is hydrogen, C.sub.1-6 alkyl or C.sub.2-4 alkenyl; and PA1 R.sup.4 is C.sub.1-6 alkyl, C.sub.2-4 alkenyl, phenyl or benzyl; PA1 provided that R.sup.3 cannot be hydrogen when Ar is unsubstituted phenyl and R.sup.4 is n-butyl. The compounds are useful in the treatment of immediate hypersensitivity diseases including asthma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.